Spark co-founder Steven Altschuler is back with an immune-resetting biotech

Drugmakers and investors have ramped up their spending and R&D attention on autoimmune diseases in recent years, with a proliferation of bispecific T cell engagers, various approaches to CAR-T cell therapy and twists on the ...